Benzinga | May 6, 2021 04:27PM EDT

Twist Bioscience Corporation Sees FY21 Sales $121M-$129M vs $120.21M Est.

Fiscal 2021 Financial Guidance

The following statements are based on Twist's current expectations for fiscal 2021. The following statements are forward-looking, and actual results could differ materially depending on market conditions and the factors set forth under "Forward-Looking Statements" below. Twist does not plan to update, nor does it undertake any obligation to update, this outlook in the future.

For the full fiscal year 2021, Twist provided the following updated financial guidance:

* Increasing revenue guidance in the range of $121 million to $129 million Revenue from Ginkgo Bioworks expected to be in the range of $11 to $12 million Synbio revenue excluding Ginkgo Bioworks is expected to be in the range of $43 to $46 million NGS revenue is estimated to be in the range of $62 to $66 million Biopharma revenue is estimated to be approximately $5 million

* Gross margin is expected to be 36% to 38% for fiscal 2021

* Operating expenses including R&D and SG&A are expected to be $192 million for the year

* Net loss expected in the range of $144 million to $150 million to reflect our increased investments in our commercial organization and research and development activities R&D is expected to be approximately $66 million Stock-based compensation is expected to be approximately $33 million Depreciation is expected to be $10 million Capital expenditures are expected to be $40 million, including expansion into "Factory of the Future"